Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
2(25%)
Results Posted
20%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_3
3
38%
Ph phase_2
3
38%

Phase Distribution

2

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 23 (37.5%)
Phase 33 (37.5%)

Trials by Status

active_not_recruiting113%
recruiting113%
terminated113%
completed563%

Recent Activity

2 active trials
Showing 5 of 8
completedphase_3

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191
active_not_recruitingphase_3

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777
recruitingphase_3

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

NCT07650084
completedphase_1

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

NCT06179537
completedphase_2

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05599191Phase 3

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Completed
NCT05600777Phase 3

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Active Not Recruiting
NCT07650084Phase 3

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

Recruiting
NCT06179537Phase 1

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

Completed
NCT04693195Phase 2

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

Completed
NCT04678206Phase 2

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Completed
NCT03979638Phase 2

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

Terminated
NCT03638180Phase 1

BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8